Literature DB >> 17307639

Repeated infliximab therapy after serum sickness-like reaction in Crohn's disease.

Pál Miheller, Györgyi Muzes, Gábor Lakatos, Emese Mihály, Zsolt Tulassay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17307639     DOI： 10.1016/j.jemermed.2006.12.005

Source DB:  PubMed          Journal:  J Emerg Med        ISSN： 0736-4679            Impact factor:   1.484


× No keyword cloud information.
  4 in total

Review 1.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

Review 2.  Infliximab-Related Infusion Reactions: Systematic Review.

Authors:  Lev Lichtenstein; Yulia Ron; Shmuel Kivity; Shomron Ben-Horin; Eran Israeli; Gerald M Fraser; Iris Dotan; Yehuda Chowers; Ronit Confino-Cohen; Batia Weiss
Journal:  J Crohns Colitis       Date:  2015-06-19       Impact factor: 9.071

Review 3.  Manipulating bone disease in inflammatory bowel disease patients.

Authors:  Pal Miheller; William Gesztes; Peter L Lakatos
Journal:  Ann Gastroenterol       Date:  2013

4.  Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study.

Authors:  Pál Miheller; Péter L Lakatos; Gábor Horváth; Tamás Molnár; Tamás Szamosi; Zsófia Czeglédi; Agnes Salamon; József Czimmer; György Rumi; Károly Palatka; Mária Papp; Zsolt Jakab; Andrea Szabó; András Gelley; László Lakatos; Zsolt Barta; Csaba Balázs; István Rácz; Margit Zeher; Zoltán Döbrönte; István Altorjay; Béla Hunyady; László Simon; János Papp; János Banai; Ferenc Nagy; János Lonovics; László Ujszászy; Györgyi Muzes; László Herszényi; Zsolt Tulassay
Journal:  BMC Gastroenterol       Date:  2009-09-10       Impact factor: 3.067
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.